Form 4: Orchestra BioMed Holdings Director Chris Cleary Receives Stock Awards

Director Chris Cleary of Orchestra BioMed Holdings receives restricted stock units and stock options.

Summary

• Chris Cleary, a director at Orchestra BioMed Holdings, received an award of 10,155 restricted stock units (RSUs) and 30,742 stock options on February 3, 2025.
• The RSUs vest in installments, with 2,987 vesting on June 24, 2025, and the remaining 7,168 vesting in three equal annual installments starting February 3, 2026, contingent upon continuous service.
• The stock options also vest in installments, with 9,223 vesting on June 24, 2025, and the remaining 21,519 vesting in three equal annual installments starting February 3, 2026, contingent upon continuous service.
• The exercise price for the stock options is $5.58, and they expire on February 3, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of equity compensation, which is generally viewed positively as it aligns management interests with shareholders. The vesting schedule promotes long-term commitment.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the awarded securities.

Industry Context

Stock awards are a common practice in the biotech industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. The vesting schedule is typical for such awards.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• Vesting schedules of three to four years are common to ensure long-term commitment.
• The specific number of options and RSUs granted would need to be compared to peer companies of similar size and stage of development to assess relative generosity.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize the director to work towards increasing shareholder value.
• The director benefits from the potential future value of the RSUs and stock options.

Key Dates